• Publications
  • Influence
Synovial cyst of spinal facet. Case report.
TLDR
The authors report a case in which a true synovial cyst was found attached to a cervical facet joint, and the anatomically oriented term “juxta-facet cyst” is proposed to include both ganglion and synovIAL cysts seen in this area. Expand
Phase I-II study of radiopeptide 177Lu-octreotate in combination with capecitabine and temozolomide in advanced low-grade neuroendocrine tumors.
TLDR
(177)Lu-octreotate, in combination with capecitabine and temozolomide, is well tolerated in patients with advanced low-grade NETs, and shows substantial tumor control rates. Expand
Multicenter phase II clinical study of iodine-131-rituximab radioimmunotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma.
TLDR
131I-rituximab radioimmunotherapy of relapsed or refractory indolent NHL achieves high ORR and CR rates with minimal toxicity. Expand
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours
TLDR
The addition of capecitabine radiosensitizing chemotherapy does not increase the minimal toxicity of 177Lu-octreotate radiopeptide therapy and led to an ORR of 24% PR and 70% minor response or SD in patients with progressive metastatic NETs. Expand
A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases.
TLDR
153Sm-EDTMP is effective for the amelioration of pain due to disseminated skeletal metastases particularly with carcinoma of breast or prostate where 83% of patients experienced pain relief. Expand
A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediaminetetramethylene phosphonate.
TLDR
A phase II study of 153Sm ethylenediaminetetramethylene phosphonate palliative treatment was conducted on 23 patients with painful disseminated skeletal metastases and the median duration of pain control and survival were substantially greater than for patients treated with a single dose. Expand
Pancreatic Neuroendocrine Tumor Control: Durable Objective Response to Combination 177Lu-Octreotate-Capecitabine-Temozolomide Radiopeptide Chemotherapy
TLDR
Combined 177Lu-octreotate-capecitabine-temozolomide radiopeptide chemotherapy is a well-tolerated, highly effective outpatient regimen for control of advanced progressive pNETs, achieving a durable objective response. Expand
Review of Gallium-68 PSMA PET/CT Imaging in the Management of Prostate Cancer
TLDR
68Ga-PSMA is the diagnostic positron-emitting theranostic pair with the beta emitter Lutetium-177 PSMA and alpha-emitter Actinium-225 PSMA which can both be used to treat PSMA-avid metastases of prostate cancer in the molecular tumor-targeted approach of the Branostic nuclear oncology. Expand
Hematological Toxicity of Combined 177Lu-Octreotate Radiopeptide Chemotherapy of Gastroenteropancreatic Neuroendocrine Tumors in Long-Term Follow-Up
TLDR
The modest reversible hematological toxicity of PRRT of GEP NETs is not significantly increased by the addition of radiosensitizing chemotherapy with capecitabine and temozolomide in combination with 177Lu-octreotate, which has the potential to enhance the efficacy of radiopeptide therapy. Expand
Continuous imaging of regional myocardial blood flow in dogs using krypton-81m.
TLDR
The unique physical properties of the freely diffusible gas krypton-81 m allowed continuous imaging of regional myocardial blood flow in dogs when infused into the aortic root when treating transient coronary artery occlusion. Expand
...
1
2
3
4
5
...